HYFT

Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

ReefIQ turns fragmented biological data into governed, queryable context for AI-enabled drug discovery and biologics development. MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, linking fragmented data into MindWalk's biological representation foundation. Sequences, structures, assay outputs

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

HYFT® technology computationally identified and prioritized a pan-serotype dengue target before immunization. Preclinical data support the prediction at the binding level: immunization with immunogens designed on the predicted target elicited antibodies that cross-react with antigens of all four dengue serotypes, and scrambled-sequence controls support that the response is specific to the designed immunogen rather than background reactivity. MindWalk Holdings Corp. (NASDAQ:HYFT) today reported preclinical dengue data that support a computational prediction its HYFT® platform generated before any animal was immunized. HYFT® computationally identified a candidate pan-serotype structural tar

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk Holdings Corp. (NASDAQ:HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The Platform draws on the same biological intelligence infrastructure that has supported more than 20 molecules advanced to the clinic across the Company's programs, and is currently deployed on its wholly owned pan-serotype Dengue and universal Influenza programs, both at in vivo proof-of

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is

SCHEDULE 13G/A - MindWalk Holdings Corp. (0001715925) (Subject)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform MindWalk Holdings Corp. (NASDAQ:HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time. Revenue for Q3 was $4.2 million, a 52 percent increase from $2.7 million in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year revenue growth. US revenue doubled year over year to $2.6 million

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual property MindWalk Holdings Corp. (NASDAQ:HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

The Company to host an earnings conference call via webcast MindWalk Holdings Corp. (NASDAQ:HYFT) ("MindWalk" or the "Company"), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal year 2026 and host a conference call on Thursday, March 12, 2026, at 10:30 AM Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast Details The live webcast will take place on Thursday, March 12, 2026, at 10:30AM ET. The conference call will be webcast live and availa

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk Holdings Corp. (NASDAQ:HYFT) ("MindWalk" or the "Company"), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequence-alignment-based analysis often fails to capture. Using HYFT® technology, MindWalk found a shared biological "signature" in influenza that stays consistent even when the virus's genetic code changes a lot. This supports MindWalk'

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ:HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer's disease. The work demonstrates MindWalk's ability to discriminate with structural precision between toxic protein conformations and their healthy counterparts, a long-standing challenge in neurodegenerative drug development. By defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, the Company is resolvin